Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab Plus Capecitabine and Oxaliplatin (C-CO2) in KRAS Wild Type Metastatic Colorectal Cancer
NCT00444678Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Jun 2004
- Primary completion
- Aug 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in metastatic colorectal cancer (mCRC), sponsored by NYU Langone Health. Primary endpoint: Response Rate for the Combination Treatment at 6 months. Started Jun 2004; status: completed.
02
Drugs
KL-140
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00444678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00444678.